Moreover, treatment with antibodies to SIRPα or to CD47 promoted antigen cross-priming of CD8+ T cells by cDC2s [113] as well as enhanced the antitumor effect mediated by CTLs in a mouse syngeneic tumor model in vivo [114]. The gene discussed is CD8A; the disease is neoplasm.